14. Rosenberg SA. Special Report: Observations on the systemic administration of 
autologous lymphokine-activated killer cells and recombinant interleukin-2 in 
patients with metastatic cancer. NEJM 313: 1485-96; 1985. 
15. Rosenberg SA, Lotze MT, Muul L et al. A progress report on treatment of 157 
patients with advanced cancers using lymphokine-activated killer cells and 
interleukin-2 or high dose interleukin-2 alone. NEJM 316:889-97; 1987. 
16. Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 
and alpha interferon for treatment of patients with advanced cancer. J Clin Oncol 
7: 1863-74; 1989. 
17. Gansbacher B, Zier K, Daniels B et al. Interleukin-2 gene transfer into tumor cells 
abrogates tumorigenicity and induces protective immunity. J Exp Med 172:1217- 
24; 1990. 
18. Gansbacher B, Banneiji R, Daniels B et al. Retroviral vector-mediated gamma 
interferon gene transfer into tumor cells generates potent and long lasting antitumor 
immunity. Cancer Research 50:7820-5; 1990. 
19. Fearon ER, Pardoll DM, Itaya T et al. Interleukin-2 production by tumor cells 
bypass T helper function in generation of an antitumor response. Cell 60:397- 
403; 1990. 
20. Rosenberg SA, Aebersald D, Cornetta K et al. Gene transfer into humans - 
Immunotherapy of patients with advanced melanoma, using tumor-infiltrating 
lymphocytes modified by retroviral gene transduction. NEJM 323:570-8; 1990. 
21. Bemd D, Maguire H, McCue P et al. Treatment of metastatic melanoma with 
autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J 
Clin One 8: 1858-67; 1990. 
22. Darrow TL, Sligluff CL, Seigler R et al. The role of HLA class I antigens in 
recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes: Evidence 
for shared antigens. J Immuno 142:3329-35; 1989. 
23. Livingston P. Active specific immunotherapy in treatment of patients with cancer. 
In Immunology and Allergy Clinics of North America. May 1991 11:3329-35. 
24. Ebert T, Bander NH. Establishment and characterization of human renal cancer and 
normal kidney cell lines. Cancer Resea 50:553 1-36; 1990. 
25. Roehm N, Marrack P, Kappler et al. Helper signals in plaque- forming cell 
response to protein bound haptens. J Exp Med. 158:3 17-33; 1983. 
Recombinant DNA Research, Volume 15 
[933] 
